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C erebrovascu lar Disease. H. Hunt Batjer, Louis R . 
Cap I an, Lars Friberg, Ralph G. Greenlee, Jr., Thomas A. 
Kopitnik, Jr., William L. Young, eels. Lippincott-Raven 
Publishers, Philadelphia, 1997. Price: $339.25.
This is a well-written and well-illustrated comprehen­
sive standard work in the field of cerebrovascular dis­
eases. In 100 chapters and 1,226 pages, nearly all aspects 
of cerebrovascular diseases are covered. The profile of 
the book is clearly dedicated to hemorrhagic aspects of 
the stroke panorama, and excellent chapters are dedi­
cated to the pathophysiology, diagnostics, and manage­
ment of arteriovenous malformations (AVM) and cranial 
aneurysms. Technical aspects of surgical and interven­
tional treatment of AVM and aneurysms are discussed in 
an excellent way and are well illustrated. The book con­
tains several well-balanced chapters in which the differ­
ent technical approaches to treatment of AVM and an­
eurysms are excellently discussed with pro et contra.
Throughout the 1,226 pages, elegant drawings, fig­
ures, and tables illustrate the text. The images in several 
chapters are of such high quality that even someone other 
than a neurosurgeon can get a good impression of the 
anatomy and the surgical problems.
The first chapters of the book are dedicated to a dis­
cussion of the cerebral vasculature in health and disease, 
with an excellent summary of anatomy, brain function, 
blood flow, and metabolism.
Section two covers diagnosis in stroke and illustrates 
well all the recent techniques applied in the field. In 
about 300 pages, ischemic stroke, syndromes, and treat­
ment are discussed. The last 600 pages deal with hem­
orrhagic stroke. Rather small parts of the book discuss 
the medical treatment of ischemic stroke. Epilepsy is not 
dealt with as such in this book, but in many chapters 
there are references to seizures as a consequence of the 
different forms of cerebrovascular disease.
The editors have succeeded in selecting an excellent 
group of co-authors and have also succeeded in making 
this a most readable book. However, in some of the 
chapters the same treatment strategies are discussed, but 
not always with the same result. This is just a tiny criti­
cism and, in fact, does not influence the main impression 
of the book. In some of the chapters the reference list 
seems somewhat outdated, stopping at 1990.
In my review copy of the book a few of pages unfor­
tunately were upside down, which did not spoil the plea­
sure of reading.
Finally, on closing the book you get a pleasant feeling of 
having read what there is to know about cerebrovascular 
disease, especially hemorrhagic stroke and even the ethical
aspects of cerebrovascular care and the role of clinical tri­
als. The book is warmly recommended to all physicians, 
especially those working in the field of cerebrovascular 
disorder. For epileptologists this is a useful book to under­
stand the disorder that is a main cause of epilepsy.
Carsten Wikkelso 
Goteborg, Sweden
Economic Evaluation of Epilepsy Management. Pro­
ceedings of the Symposium on Economic Aspects of 
Epilepsy at the 21st International Epilepsy Congress in 
Sydney in 1995. Christoph Pachlatko and Roy G. Beran, 
eds. John Libbey, London, 1996. 112 pp. Price: $37.00.
This is the second publication of the Commission on 
Economic Aspects of ILAE. The present book offers a 
broad and comprehensive overview of the current meth­
ods and activities undertaken to introduce economic as­
pects in the evaluation of the management of epilepsy.
In Chapters 1 and 2, an introduction is given to basic 
factors to be considered in economic evaluations, as well as 
to possible study methodologies to be applied in economic 
studies. The fact that financial resources are limited in all 
societies and that political decisions are often based on 
economic arguments stands in contrast to the situation that 
little is known about the real costs of epilepsy and the 
economic benefits of any treatment. A sound basis is 
needed for the cost calculation based on epidemiologic 
findings and characterization of costs. Direct as well as 
indirect costs have to be considered. Furthermore, tools to 
measure outcome in domains such as quality of life are 
badly needed to assess effectiveness of interventions.
Chapter 3 gives an introduction to the Epilepsy Founda­
tion of America study currently under way in the United 
States. Up to now, only two studies have been published on 
the cost of epilepsy in the U.S. The described study, there­
fore, should contribute to the knowledge of the social bur­
den of epilepsy. Prevalence- as well as incidence-based 
direct and indirect costs will be calculated to gain estimates 
on the national costs of epilepsy.
Chapters 4 to 6 deal with the experiences gained in Aus­
tralia, where, since 1993, economic evaluations have been 
mandatory for approval of a new treatment for reimburse­
ment. Australia is the first country in the world to ask for 
such studies. A first optional version was introduced in 
1990. Up to now, registration has been based on quality, 
safety, and efficacy of a treatment, but usually no compari­
sons as to economic advantages are undertaken for regula­
tory purposes. After 5 years’ experience, it has been shown 
that economic evaluations are effective as a discriminating 
tool and also serve as a basis for price negotiation.
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A move towards evidence-based decision making can 
be seen as well. In contrast to Canada, where similar 
studies are now required, the Australian studies are fo­
cused specifically on direct costs. They had to incorpo­
rate assumptions as to resource utilization and, to date, 
there have been no studies published to confirm or refute 
these assumptions.
Finally, in chapters 7 to 9, three economic studies are 
presented. The study from Canada on the introduction of 
vigabatrin (VGB) shows an example of the kind of eco­
nomic studies that are now mandatory by regulatory affairs. 
It provides information on the expected economic conse­
quences of introducing VGB from the point of view of a 
health-care system. But such studies do not take into con­
sideration the effects on quality of life or on indirect costs.
The study conducted in Sweden (chapter 8) deals with 
the change in indirect costs by epilepsy surgery. A reduc­
tion of the indirect costs as well as socioeconomic effects of 
epilepsy and epilepsy surgeiy can be shown. This is in 
contrast to the high direct costs of this treatment. This as­
pect is highlighted by the study on epilepsy surgery in 
Colombia (chapter 9). It illustrates that epilepsy surgery can 
be successfully performed to a high standard in developing 
countries at considerably lower costs than in developed 
countries. The fact that the results come from a subsidized 
private non-profit organization and that no correlation to 
national economic figures is made unfortunately limits the 
usefulness of this study.
Overall, the compilation gives a profound survey of 
the current knowledge and activities in the attempt to 
also economically evaluate the management of a certain 
disease syndrome. Other related aspects, such as the 
problem of humanitarian benefit versus economic gain, 
as well as ethical considerations when performing eco­
nomic studies, are not discussed in this book, but should 
definitely be addressed in future activities in this field.
Stephanie Natsch 
University Hospital Nijmegen
The Netherlands
Behavioral Neurology and the Legacy of Norman 
Geschwind* Steven C. Schächter and Orrin Devinski, 
eds. Lippincott-Raven Publishers, Philadelphia, 1997, 
304 pp., Price: $126.50.
In the mind of many neurologists, Norman Geschwind’s 
contribution to neurology and neuropsychology will remain 
associated with Ms landmark work on disconnection syn­
dromes. Reading “Behavioral Neurology and the Legacy of 
Norman Geschwind” reaffirms this belief, but also opens a 
wide spectrum of Geschwind’s other contributions in dif­
ferent subfields of neurology, such as aphasia, dyslexia, 
autism, epilepsy, and dementia. This multi-authored book is 
divided into 5 parts.
The initial part provides a forum for personal perspec­
tives on Geschwind. Former colleagues and students tes­
tify as privileged witnesses of his keen intelligence, 
teaching skills, mentorship, and deep human aspirations.
In the part on language disorders, several authors de­
scribe Geschwind’s influence on the study of aphasia, the 
evolving concepts of anomia, dyslexia, and stuttering. The 
neurolinguistic models proposed by Geschwind and co­
workers were based on a thorough study and analysis of the 
work of late 19th and early 20th century scientists, such as 
Wemiche, Liepman, Dejerine, and Broca, and also lesser 
known researchers. In aphasia, the major influence of 
Geschwind was to initiate the change from the prevailing 
holistic to brain-oriented language investigations.
In the third part, Geschwind’s contributions to discon­
nection, attention disorders, autism, dementia, and apraxia 
are described and commented on by several authorities in 
the respective fields. His two-part treatise “Disconnexion 
Syndromes in Animals and Man” represents Geschwind’s 
most powerful and persisting influence in neurology. He 
united old German and French literature with recent ana­
tomical, physiological, and clinical data,
In the part on epilepsy, Schomer and Devinski illustrate 
the ability of Geschwind to synthesize large volumes of 
data and see relationships that were not apparent to his 
peers. David Bear explains die concept of the “Geschwind 
syndrome,” a syndromic change in behavior, hypergraphia, 
religiosity, hyposexuality, aggressiveness, and stickiness 
described by Geschwind and Waxman. Herzog elucidates 
the relationship between neuroendocrine function and tem­
poral lobe epilepsy that Geschwind established.
In the final part on handedness, cerebral dominance, and 
autoimmune disease, the reader gets a cross-section of re­
search in the field that was greatly inspired by Geschwind’s 
work during his last years. In collaboration with Behan, he 
showed that there was a significant increase in the inci­
dence of stuttering, dyslexia, colitis, thyroid disease, and 
myasthenia gravis in the population of strong left-handers. 
He also found significant associations between laterality 
and learning disabilities, blond hair and occupation.
As Galaburda explains in his epilogue, Norman 
Geschwind5 s work “evolved from the reestablishment of 
classic thinking to the forging of new frontiers, reinforcing 
the idea that in order to make progress, it is necessary to 
know the useful past,” Besides an astute clinician who 
cared about the well-being of his patients, Geschwind was 
a great scientist with an intuitive and “architectural” vision.
Despite the presence of some redundancy between dif­
ferent chapters, which is to be expected in this type of 
book, “Behavioral Neurology and the Legacy of Norman 
Geschwind” is informative, pleasant, and inspiring both 
to a general neurological audience and to epileptologists.
Paul A.J.M. Boon 
Gent, Belgium
Epilepsia, Vol. 38, No. 10, 1997
